Literature DB >> 19239775

Guillain-Barré syndrome after chikungunya infection.

Gaëtan Lebrun, Karim Chadda, Anne-Hélène Reboux, Olivier Martinet, Bernard-Alex Gaüzère.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19239775      PMCID: PMC2681104          DOI: 10.3201/eid1503.071482

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Chikungunya virus is an RNA alphavirus (group A arbovirus) in the family Togaviridae. The known vectors are Aedes aegypti and Ae. albopictus mosqitoes. Chikungunya infection, after an incubation period of 2–10 days, has the main clinical manifestations of fever, polyarthralgia, and rash. Treatment consists of rest and medication for pain. Outcome is marked by incapacitating arthralgia, which can persist for several weeks or months (). Complications are rare and consist of mild hemorrhage, myocarditis, and hepatitis (). Neurologic manifestations are less well known (). Infection is confirmed by the identification of genomic products in acute-phase blood specimens, (reverse transcription–PCR [RT-PCR]) or, more recently, by serum immunoglobulin (Ig) M or a 4-fold increase in other antibodies. In 2006, chikungunya virus was found on Réunion Island; seroprevalence on the island was estimated to be 38.2% among 785,000 inhabitants (95% confidence interval 35.9%–40.6%) (). Guillain-Barré syndrome (GBS) is an acute inflammatory demyelinating polyneuropathy; incidence worldwide is 0.6–4/100,000 persons/year. In two thirds of patients, neuropathic GBS occurs after an infection (,). Cases of GBS have been described in association with the arboviruses dengue and West Nile but not with chikungunya virus. We report 2 cases of acute and severe GBS related to infection with chikungunya virus. The first patient was a 51-year-old woman who in 2006 was admitted to an intensive care unit in Réunion Island’s Centre Hospitalier Departemental for treatment of polyradiculoneuropathy. Her medical history consisted of poorly treated type 2 diabetes and hypertension. Three weeks before hospital admission, she had had fever, arthralgia, rash, and diarrhea. One week later, rapidly progressing motor weakness and sensory disturbances developed, e.g., tingling in all limbs. She had facial diplegia, and her tendon reflexes were absent. Cerebrospinal fluid (CSF) contained increased protein (1.44 g/L) but not increased leukocytes (1/mm3). Electromyography displayed typical signs of demyelinating sensorimotor neuropathy with increased distal motor latency and reduced motor conduction velocity. Sensory nerve action potential was absent. Antichikungunya IgM was found in serum at 15 days after onset of signs and symptoms. This seroconversion confirms an acute infection by an alphavirus. Serum genomic product (RT-PCR, TaqMan method) () was negative for chikungunya virus. Antichikungunya IgM and IgG were also found in CSF. The patient’s respiration rapidly deteriorated, and she required tracheal intubation and mechanical ventilation for 12 days. She was given intravenous immunoglobulin for 5 days (TEGELINE; LBF Biomedicaments, Courtaboeuf, France). She recovered and was extubated on day 12. Two months after onset of symptoms, the patient reported a satisfactory recovery; she was able to walk, and her sensory disturbances had rapidly disappeared. The second patient was a 48-year-old woman who in 2006 was admitted to the intensive care unit in Réunion Island’s Centre Hospitalier Departemental unit for a rapidly developing polyradiculoneuropathy. She had no relevant past medical history. Two weeks before her admission, she had been febrile and had had arthralgia and a rash. Later, weakness with facial diplegia and sensory disturbances developed, e.g., tingling in all limbs. Tendon reflexes were absent. CSF contained increased protein but not increased leukocytes. Electromyography displayed signs of a peripheral neuropathy and evidence of a conduction block. At the time of hospital admission, antichikungunya IgM and IgG were detected in 2 serum samples. RT-PCR for chikungunya virus in serum and CSF was negative. The patient’s respiration rapidly deteriorated, and she required tracheal intubation and mechanical ventilation for 9 days. After receiving intravenous immunoglobulin for 5 days, she recovered quickly. Return of a productive cough and satisfactory muscle tone enabled her to be removed from mechanical ventilation on day 9. For the 2 patients reported here, GBS diagnosis was based on a typical clinical acute motor and sensory polyradiculoneuropathy, which evolved in 3 characteristic stages: rapid deterioration, plateau, and slow recovery (). Also typical of GBS are normal CSF counts, increased CSF proteins, and electromyography data (peripheral neuropathy, conduction block). The widespread screening for organisms known to be associated with GBS produced negative results. However, antichikungunya IgM was found in serum and CSF, although genomic products in serum and CSF were negative, which was not surprising, given the brief period (4–5 days) of viremia (). These findings strongly supported a disseminated acute chikungunya infection and enabled us to conclude that chikungunya virus was probably responsible for the GBS. Epidemiologic data also support a causal relationship between chikungunya infection and GBS. The incidence rate of GBS increased ≈22% in 2006 (26/787,000 [3.3/100,000] persons) over the rate in 2005 (21/775,000 [2.7/10,000] persons) and then declined to a rate closer to baseline in 2007 (23/800,000 [2.87/100,000] persons). These 2 cases of GBS on Réunion Island were related to an acute and documented chikungunya infection. In the absence of an effective treatment, patients with these suspected infections should receive supportive care for classic GBS.
  7 in total

1.  [Acute neurologic and sensorial disorders in dengue and Chikungunya fever].

Authors:  R Mazaud; J J Salaün; H Montabone; P Goube; R Bazillio
Journal:  Bull Soc Pathol Exot Filiales       Date:  1971 Jan-Feb

Review 2.  Guillain-Barré syndrome.

Authors:  Richard A C Hughes; David R Cornblath
Journal:  Lancet       Date:  2005-11-05       Impact factor: 79.321

3.  Development of a TaqMan RT-PCR assay without RNA extraction step for the detection and quantification of African Chikungunya viruses.

Authors:  Boris Pastorino; Maël Bessaud; Marc Grandadam; Severine Murri; Hugues J Tolou; Christophe N Peyrefitte
Journal:  J Virol Methods       Date:  2004-12-15       Impact factor: 2.014

4.  Chikungunya infection--an emerging disease in Malaysia.

Authors:  S K Lam; K B Chua; P S Hooi; M A Rahimah; S Kumari; M Tharmaratnam; S K Chuah; D W Smith; I A Sampson
Journal:  Southeast Asian J Trop Med Public Health       Date:  2001-09       Impact factor: 0.267

5.  Chikungunya virus infection. A retrospective study of 107 cases.

Authors:  S W Brighton; O W Prozesky; A L de la Harpe
Journal:  S Afr Med J       Date:  1983-02-26

6.  Arboviral infections of the central nervous system--United States, 1996-1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1998-07-03       Impact factor: 17.586

7.  Estimating Chikungunya prevalence in La Réunion Island outbreak by serosurveys: two methods for two critical times of the epidemic.

Authors:  Patrick Gérardin; Vanina Guernier; Joëlle Perrau; Adrian Fianu; Karin Le Roux; Philippe Grivard; Alain Michault; Xavier de Lamballerie; Antoine Flahault; François Favier
Journal:  BMC Infect Dis       Date:  2008-07-28       Impact factor: 3.090

  7 in total
  39 in total

1.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

Review 2.  Guillain-Barré syndrome--a classical autoimmune disease triggered by infection or vaccination.

Authors:  Eitan Israeli; Nancy Agmon-Levin; Miri Blank; Joab Chapman; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

3.  Case reports of neuro-Chikungunya in southern Thailand.

Authors:  Sarunyou Chusri; Pisud Siripaitoon; Siriporn Hirunpat; Khachornsakdi Silpapojakul
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

Review 4.  Four emerging arboviral diseases in North America: Jamestown Canyon, Powassan, chikungunya, and Zika virus diseases.

Authors:  Daniel M Pastula; Daniel E Smith; J David Beckham; Kenneth L Tyler
Journal:  J Neurovirol       Date:  2016-02-22       Impact factor: 2.643

Review 5.  Current concerns and perspectives on Zika virus co-infection with arboviruses and HIV.

Authors:  Hussin A Rothan; Mehdi R M Bidokhti; Siddappa N Byrareddy
Journal:  J Autoimmun       Date:  2018-01-17       Impact factor: 7.094

Review 6.  Mouse models for Chikungunya virus: deciphering immune mechanisms responsible for disease and pathology.

Authors:  Teck-Hui Teo; Fok-Moon Lum; Wendy W L Lee; Lisa F P Ng
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 7.  The Range of Neurological Complications in Chikungunya Fever.

Authors:  T Cerny; M Schwarz; U Schwarz; J Lemant; P Gérardin; E Keller
Journal:  Neurocrit Care       Date:  2017-12       Impact factor: 3.210

8.  Guillain-Barré Syndrome and Chikungunya: Description of All Cases Diagnosed during the 2014 Outbreak in the French West Indies.

Authors:  Stephanie Balavoine; Mathilde Pircher; Bruno Hoen; Cecile Herrmann-Storck; Fatiha Najioullah; Benjamin Madeux; Aissatou Signate; Ruddy Valentino; Annie Lannuzel; Magali Saint Louis; Sylvie Cassadou; André Cabié; Kinda Schepers
Journal:  Am J Trop Med Hyg       Date:  2017-07-19       Impact factor: 2.345

9.  Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study.

Authors:  Van-Mai Cao-Lormeau; Alexandre Blake; Sandrine Mons; Stéphane Lastère; Claudine Roche; Jessica Vanhomwegen; Timothée Dub; Laure Baudouin; Anita Teissier; Philippe Larre; Anne-Laure Vial; Christophe Decam; Valérie Choumet; Susan K Halstead; Hugh J Willison; Lucile Musset; Jean-Claude Manuguerra; Philippe Despres; Emmanuel Fournier; Henri-Pierre Mallet; Didier Musso; Arnaud Fontanet; Jean Neil; Frédéric Ghawché
Journal:  Lancet       Date:  2016-03-02       Impact factor: 79.321

Review 10.  Zika Virus.

Authors:  Didier Musso; Duane J Gubler
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.